Abstract
Histone deacetylase (HDAC) inhibitors are a group of anticancer drugs which cause growth arrest and apoptosis of several tumor cells. HDAC inhibitors have been also found to increase the anticancer efficacy of several treatment modalities i.e. chemotherapy or radiotherapy. Here, we review the literature on combinations of HDAC inhibitors both with ionizing radiation and with other drugs, highlighting DNA-damaging compounds. The results of numerous studies with several types of cancer cells discussed in this review demonstrate that HDAC inhibitors enhance the effect of DNA damaging agents, such as inhibitors of topoisomerases, inhibitors of DNA synthesis, DNA-intercalators and agents covalently modifying DNA (i.e. doxorubicin, etoposid, 5-fluorouracil, cisplatin, melphalan, temozolomide and ellipticine) or of irradiation. Hence, the use of HDAC inhibitors combined with these antitumor drugs or ionizing radiation is a promising tool which may make treatment of patients suffering from many types of cancer more efficient. Several molecular mechanisms are responsible for the observed higher sensitivity of tumor cells towards therapeutic agents elicited by HDAC inhibitors. These mechanisms are discussed also in this review.
Keywords: Chromatin remodeling, histone acetylation, histone deacetylase, histone deacetylase inhibitor, anticancer drugs, DNA-damaging drugs, ionizing radiation, combined treatment modalities, mechanisms of combined treatment, apoptosis
Current Medicinal Chemistry
Title:The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Volume: 19 Issue: 25
Author(s): M. Stiborova, T. Eckschlager, J. Poljakova, J. Hrabeta, V. Adam, R. Kizek and E. Frei
Affiliation:
Keywords: Chromatin remodeling, histone acetylation, histone deacetylase, histone deacetylase inhibitor, anticancer drugs, DNA-damaging drugs, ionizing radiation, combined treatment modalities, mechanisms of combined treatment, apoptosis
Abstract: Histone deacetylase (HDAC) inhibitors are a group of anticancer drugs which cause growth arrest and apoptosis of several tumor cells. HDAC inhibitors have been also found to increase the anticancer efficacy of several treatment modalities i.e. chemotherapy or radiotherapy. Here, we review the literature on combinations of HDAC inhibitors both with ionizing radiation and with other drugs, highlighting DNA-damaging compounds. The results of numerous studies with several types of cancer cells discussed in this review demonstrate that HDAC inhibitors enhance the effect of DNA damaging agents, such as inhibitors of topoisomerases, inhibitors of DNA synthesis, DNA-intercalators and agents covalently modifying DNA (i.e. doxorubicin, etoposid, 5-fluorouracil, cisplatin, melphalan, temozolomide and ellipticine) or of irradiation. Hence, the use of HDAC inhibitors combined with these antitumor drugs or ionizing radiation is a promising tool which may make treatment of patients suffering from many types of cancer more efficient. Several molecular mechanisms are responsible for the observed higher sensitivity of tumor cells towards therapeutic agents elicited by HDAC inhibitors. These mechanisms are discussed also in this review.
Export Options
About this article
Cite this article as:
Stiborova M., Eckschlager T., Poljakova J., Hrabeta J., Adam V., Kizek R. and Frei E., The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment, Current Medicinal Chemistry 2012; 19 (25) . https://dx.doi.org/10.2174/092986712802884286
DOI https://dx.doi.org/10.2174/092986712802884286 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Insight into the Inflammatory and Cellular Responses Following Experimental Glaucoma Surgery: A Roadmap for Inhibiting Fibrosis
Current Molecular Medicine Nanomaterials in the Pharmaceuticals: Occurrence, Behaviour and Applications
Current Pharmaceutical Design Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics β-Glucuronidase Inhibitory Studies on Coumarin Derivatives
Medicinal Chemistry Targeted Ultrasound Imaging of Cancer: An Emerging Technology on its Way to Clinics
Current Pharmaceutical Design Overview of the Formulations and Analogs in the Taxanes' Story
Current Medicinal Chemistry Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets FTY720: A Most Promising Immunosuppressant Modulating Immune Cell Functions
Mini-Reviews in Medicinal Chemistry Inflammatory and Non-Inflammatory Roles for Toll-Like Receptors in Gastrointestinal Cancer
Current Pharmaceutical Design E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry The Life and Death of Protein Kinase C
Current Drug Targets Molecular Mechanisms and Proposed Targets for Selected Anticancer Gold Compounds
Current Topics in Medicinal Chemistry Alternative Spliced Variants as Biomarkers of Colorectal Cancer
Current Drug Metabolism Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges
Current Drug Delivery Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Four-Component Synthesis of 1,2-Dihydropyridine Derivatives and their Evaluation as Anticancer Agents
Medicinal Chemistry Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Role of Active Drug Transporters in Refractory Multiple Myeloma
Current Topics in Medicinal Chemistry